Windward Bio is a clinical-stage drug development company based in Switzerland, focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is developing a novel long-acting monoclonal antibody targeting the TSLP ligand and is building a discovery pipeline of long-acting bispecifics to address high unmet medical needs and reduce treatment burdens globally.
Leadership & Board
Current Number of Employees48
Current LinkedIn Followers4,264
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$200M
Total Amount Raised$200M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$200M
Latest Funding Amount$200M
Latest Funding RoundSeries A
Latest Funding RoundSeries A
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
Windward Bio had 48 employees as of September 7, 2026. The number of employees increased by 0 (0.00%) week-over-week.
48Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
Windward Bio had 4,264 followers as of September 7, 2026. The number of followers increased by 87 (2.08%) week-over-week.
4,264Latest Followers Count
87(2.08%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.